selpercatinib
E561036
Selpercatinib is a targeted cancer therapy drug that selectively inhibits RET kinase to treat certain RET-altered thyroid and non-small cell lung cancers.
Statements (47)
| Predicate | Object |
|---|---|
| instanceOf |
RET inhibitor
ⓘ
small molecule drug ⓘ targeted cancer therapy ⓘ tyrosine kinase inhibitor ⓘ |
| approvedBy | U.S. Food and Drug Administration NERFINISHED ⓘ |
| belongsToChemicalClass | small-molecule kinase inhibitors ⓘ |
| developedBy | Eli Lilly and Company NERFINISHED ⓘ |
| firstApprovalYear | 2020 ⓘ |
| firstApprovedIn | United States NERFINISHED ⓘ |
| hasAdministrationFrequency | twice daily in many regimens ⓘ |
| hasApprovalType | accelerated approval (initial US approval) ⓘ |
| hasATCCode | L01EX19 ⓘ |
| hasBlackBoxWarning | none (as of initial approval) ⓘ |
| hasBrandName | Retevmo NERFINISHED ⓘ |
| hasCommonAdverseEffect |
constipation
ⓘ
diarrhea ⓘ dry mouth ⓘ edema ⓘ elevated liver enzymes ⓘ fatigue ⓘ hypertension ⓘ |
| hasDosageForm | capsule ⓘ |
| hasDrugInteraction |
strong CYP3A inducers
ⓘ
strong CYP3A inhibitors ⓘ |
| hasIndicationPopulation |
adult patients
ⓘ
pediatric patients 12 years and older ⓘ |
| hasINN | selpercatinib ⓘ |
| hasMechanismOfAction |
inhibition of RET-mediated signaling pathways
ⓘ
selective RET kinase inhibition ⓘ |
| hasMolecularTargetType | receptor tyrosine kinase ⓘ |
| hasPregnancyRisk | may cause fetal harm ⓘ |
| hasRouteOfAdministration | oral ⓘ |
| hasSelectivity | highly selective for RET over many other kinases ⓘ |
| hasSeriousAdverseEffect |
QT interval prolongation
ⓘ
hemorrhagic events ⓘ hepatotoxicity ⓘ interstitial lung disease ⓘ |
| hasTarget |
RET kinase
NERFINISHED
ⓘ
rearranged during transfection proto-oncogene ⓘ |
| indicatedFor |
RET fusion-positive non-small cell lung cancer
ⓘ
RET-mutant medullary thyroid carcinoma ⓘ advanced RET fusion-positive thyroid cancer ⓘ metastatic RET fusion-positive non-small cell lung cancer ⓘ metastatic RET-mutant medullary thyroid cancer ⓘ |
| isAdministered | by mouth ⓘ |
| isMetabolizedBy | CYP3A4 NERFINISHED ⓘ |
| isTakenWithFood | may be taken with or without food ⓘ |
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.
subject surface form:
Loxo Oncology
subject surface form:
Loxo Oncology